{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:19:51Z","timestamp":1769278791943,"version":"3.49.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1016\/s1367-5931(99)80068-4","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T13:27:54Z","timestamp":1027603674000},"page":"466-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents"],"prefix":"10.1016","volume":"3","author":[{"given":"Annette M","family":"Doherty","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1367-5931(99)80068-4_reference0005","first-page":"351","article-title":"Phosphodiesterase isoenzymes. Molecular targets for novel antiasthma agents","volume":"157","author":"Torphy","year":"1998","journal-title":"J Resp Crit Care Med"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1006\/bbrc.1998.8684","article-title":"Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase","volume":"246","author":"Fisher","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/S1367-5931(99)80068-4_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1517\/14728214.2.1.249","article-title":"Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease","volume":"2","author":"De Brito","year":"1997","journal-title":"Emerg Drugs"},{"key":"10.1016\/S1367-5931(99)80068-4_bib4","first-page":"5325","article-title":"Molecular cloning of rat homologues of the Drosophila melangaster dunce cAMP phosphodiesterase: evidence for a family of genes","volume":"86","author":"Swinnen","year":"1989"},{"key":"10.1016\/S1367-5931(99)80068-4_bib5","first-page":"3599","article-title":"Isolation and characterization of a mammalian gene encoding a high affinity cAMP phosphodiesterase","volume":"86","author":"Colicelli","year":"1989"},{"key":"10.1016\/S1367-5931(99)80068-4_bib6","doi-asserted-by":"crossref","first-page":"18929","DOI":"10.1016\/S0021-9258(19)37050-4","article-title":"Characterization of the structure of a low Km rolipram sensitive cAMP phosphodiesterase","volume":"267","author":"Jin","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_bib7","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1016\/S0021-9258(18)53275-0","article-title":"A low Km rolipram-sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, biochemical characterization of recombinant protein and tissue distribution of mRNA","volume":"268","author":"McLaughlin","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0378-1119(93)90274-7","article-title":"The cDNA of a human lymphocyte cyclic AMP phosphodiesterase (PDE IV) reveals a multigene family","volume":"129","author":"Obernolte","year":"1993","journal-title":"Gene"},{"key":"10.1016\/S1367-5931(99)80068-4_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0021-9258(17)42355-6","article-title":"Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases","volume":"269","author":"Monaco","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0378-1119(94)90818-4","article-title":"Isolation of cDNA encoding a human rolipram sensitive cyclic AMP phosphodiesterase (PDE IVD)","volume":"138","author":"Baecker","year":"1994","journal-title":"Gene"},{"key":"10.1016\/S1367-5931(99)80068-4_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0898-6568(97)00072-7","article-title":"Molecular cloning and expression of a human phosphodiesterase 4C","volume":"9","author":"Owens","year":"1997","journal-title":"Cell Signal"},{"key":"10.1016\/S1367-5931(99)80068-4_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/bj3280539","article-title":"Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene","volume":"328","author":"Bolger","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/S1367-5931(99)80068-4_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/bj3280549","article-title":"Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3","volume":"328","author":"Hustun","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/S1367-5931(99)80068-4_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1523-1747.1998.00114.x","article-title":"Cyclic nucleotide phosphodiesterase 4 subtypes are differently expressed by primary keratinocytes and human epidermoid cell lines","volume":"110","author":"Chujor","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0026-895X(24)23155-2","article-title":"Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes","volume":"55","author":"Ma","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/mol.53.1.23","article-title":"Characterization of the rolipram sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain","volume":"53","author":"Iona","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0085","doi-asserted-by":"crossref","first-page":"19672","DOI":"10.1074\/jbc.273.31.19672","article-title":"Subcellular localization of the rolipram sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene","volume":"273","author":"Jin","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF02737809","article-title":"Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 i mitogen-stimulated and leukemic human lymphocytes","volume":"28","author":"Jiang","year":"1998","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/S1367-5931(99)80068-4_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/bj3210165","volume":"321","author":"Erdogan","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/S1367-5931(99)80068-4_bib20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1523\/JNEUROSCI.19-02-00610.1999","article-title":"Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterases 4A and 4B isoforms","volume":"19","author":"Takahashi","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/S1367-5931(99)80068-4_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/bj3330139","article-title":"cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model","volume":"333","author":"Hoffman","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/S1367-5931(99)80068-4_bib22","doi-asserted-by":"crossref","first-page":"14250","DOI":"10.1021\/bi971112e","article-title":"Human recombinant phosphodiesterase 4B2B binds (R) -rolipram at a single site with two affinities","volume":"36","author":"Rocque","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0115","first-page":"3549","article-title":"Stimulation of p70S6 kinase via a growth hormone controlled phosphatidylinositol 3-kinase pathway leads to the activation of PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes","volume":"95","author":"MacKenzie","year":"1998"},{"key":"10.1016\/S1367-5931(99)80068-4_bib24","doi-asserted-by":"crossref","first-page":"20575","DOI":"10.1074\/jbc.273.32.20575","article-title":"Induction of phosphodiesterase 3B, 4A4, 4D1, 4D2, 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonist. Potential role in beta2-adrenoreceptor desensitization","volume":"273","author":"Seybold","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2332\/allergolint.45.125","article-title":"Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors","volume":"45","author":"Banner","year":"1996","journal-title":"Allerg Int"},{"key":"10.1016\/S1367-5931(99)80068-4_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0701115","article-title":"Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function","volume":"121","author":"Weston","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-3565(24)36796-5","article-title":"Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors","volume":"282","author":"Essayan","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(99)80068-4_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0091-6749(97)81041-X","article-title":"Differential efficacy of lymphocyte-and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen driven proliferation and cytokine gene expression","volume":"99","author":"Essayan","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(97)00071-4","article-title":"A selective type 4 phosphodiesterase inhibitor, T-440, modulates intracellular cyclic AMP level and interleukin-2 production of Jurkat cells","volume":"38","author":"Kaminuma","year":"1998","journal-title":"Immunopharmacology"},{"key":"10.1016\/S1367-5931(99)80068-4_bib30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0006-2952(97)00102-0","article-title":"Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergan-specific human T lymphocyte clones","volume":"53","author":"Essayan","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.bjp.0701688","article-title":"Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation","volume":"123","author":"Gantner","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0091-6749(98)70020-X","article-title":"Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors","volume":"102","author":"Crocker","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0091-6749(97)70146-5","article-title":"Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals; a comparative study","volume":"100","author":"Gantner","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1476-5381.1996.tb15450.x","article-title":"Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF\u03b1 generation from human monocytes by interacting with a low affinity phosphodiesterase 4 conformer","volume":"118","author":"Souness","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jlb.63.1.101","article-title":"Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production","volume":"63","author":"Bigler","year":"1998","journal-title":"J Leukoc Biol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.bjp.0701124","article-title":"In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumor necrosis factor-\u03b1 release by PDE inhibitors","volume":"121","author":"Gantner","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bjp.0702387","article-title":"The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-a and leukotriene B4 in novel human whole blood assay","volume":"126","author":"Brideau","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjp.0701376","article-title":"Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity","volume":"122","author":"Rose","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib39","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.bjp.0701243","article-title":"Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram","volume":"121","author":"Santamaria","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib40","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/j.1476-5381.1996.tb15598.x","article-title":"Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects","volume":"118","author":"Tenor","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bjp.0701833","article-title":"Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterase 3 and 4","volume":"124","author":"Blease","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000028219","article-title":"Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages","volume":"57","author":"Takei","year":"1998","journal-title":"Pharmacology"},{"key":"10.1016\/S1367-5931(99)80068-4_bib43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0028-3908(98)00190-7","article-title":"Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret","volume":"38","author":"Robichaud","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/S1367-5931(99)80068-4_bib44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/jm980314l","article-title":"Novel potent and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives","volume":"42","author":"Ukita","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0898-6568(96)00173-8","article-title":"Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases","volume":"9","author":"Souness","year":"1997","journal-title":"Cell Signal"},{"key":"10.1016\/S1367-5931(99)80068-4_bib46","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1111\/j.1600-0773.1996.tb00178.x","article-title":"The toxicity of repeated exposure of rolipram, a type IV phosphodiesterase inhibitor in rats","volume":"78","author":"Larson","year":"1996","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s002040050567","article-title":"Theophylline-induced mesenteric periarteritis in F344\/N rats","volume":"72","author":"Nyska","year":"1998","journal-title":"Arch Toxicol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.bjp.0701158","article-title":"Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type 4 phosphodiesterase inhibitors: in vitro and in vivo studies","volume":"121","author":"Kumari","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib49","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/humrep\/13.5.1248","article-title":"Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors","volume":"13","author":"Fisch","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/S1367-5931(99)80068-4_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0898-6568(98)00028-X","article-title":"Effect of pregnancy on PDE-4 cAMP-specific phosphodiesterase messenger ribonucleic acid expression in human myometrium","volume":"11","author":"Leroy","year":"1999","journal-title":"Cell Signal"},{"key":"10.1016\/S1367-5931(99)80068-4_bib51","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/dbio.1996.0226","article-title":"Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors","volume":"178","author":"Tsafriri","year":"1996","journal-title":"Devel Biology"},{"key":"10.1016\/S1367-5931(99)80068-4_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199957010-00001","article-title":"Drug treatment of asthma in the","volume":"57","author":"Tavakkoli","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/S1367-5931(99)80068-4_bib53","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0022-3565(25)20789-3","article-title":"The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4","volume":"278","author":"Turner","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(99)80068-4_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/pupt.1998.0111","article-title":"Effects of a selective PDE-4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs","volume":"11","author":"Dent","year":"1998","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/S1367-5931(99)80068-4_bib55","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1476-5381.1996.tb15522.x","article-title":"The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4","volume":"118","author":"Hughes","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000237488","article-title":"Effect of T-440, a novel type IV phosphodiesterase inhibitor on allergen induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs","volume":"112","author":"Kaminuma","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0014-2999(97)01063-7","article-title":"Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor","volume":"332","author":"Manabe","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0290","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0022-3565(24)37892-9","article-title":"Antiasthmatic activity of the second generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig","volume":"287","author":"Underwood","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(99)80068-4_bib59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1382-6689(97)00014-8","article-title":"Prevention of ozone-induced airway hyperresponsiveness and epithelial injury by phosphodiesterase inhibitors in guinea pigs","volume":"3","author":"Matsubara","year":"1997","journal-title":"Environ Toxicol Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0022-3565(24)37233-7","article-title":"Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen","volume":"284","author":"Fujii","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0305","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1358\/dof.1998.023.06.457488","article-title":"SB-207499 (Ariflo TM)","volume":"23","author":"Silvestri","year":"1998","journal-title":"Drugs Future"},{"key":"10.1016\/S1367-5931(99)80068-4_bib62","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1183\/09031936.97.10051008","article-title":"The effect of a novel orally active selective PDE-4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects","volume":"10","author":"Harbinson","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/S1367-5931(99)80068-4_bib63","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/jm970090r","article-title":"1,4-cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma","volume":"41","author":"Christensen","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0320","first-page":"91","article-title":"Phosphodiesterase inhibitors","volume":"33","author":"Burnouf","year":"1998","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0325","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0165-6147(98)01245-0","article-title":"Chronic obstructive pulmonary disease: new opportunities for drug development","volume":"19","author":"Barnes","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/S1367-5931(99)80068-4_bib66","first-page":"A522","article-title":"The efficacy of Ariflo (SB207499), a second generation, oral PDE4 inhibitor in patients with COPD","volume":"159","author":"Compton","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S1367-5931(99)80068-4_bib67","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/S0022-3565(24)36920-4","article-title":"Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries","volume":"282","author":"Wagner","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(99)80068-4_bib68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1165\/ajrcmb.18.3.2913","article-title":"Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4","volume":"18","author":"Miotla","year":"1998","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0345","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.bjp.0701649","article-title":"Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung","volume":"123","author":"Gonccalves de Moraes","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib70","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2249.1997.3931291.x","article-title":"Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram","volume":"108","author":"Nymaan","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib71","first-page":"236","article-title":"The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN\u03b3 and TNF\u03b1 mRNA expressing blood mononuclear cells in patients with multiple sclerosis","volume":"21","author":"Navikas","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0360","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-3565(24)37847-4","article-title":"SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo","volume":"287","author":"Griswold","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0365","doi-asserted-by":"crossref","first-page":"15020","DOI":"10.1073\/pnas.95.25.15020","article-title":"Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting potentiation and improves memory","volume":"95","author":"Barad","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1367-5931(99)80068-4_bib74","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1097\/00001756-199712010-00033","article-title":"Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats","volume":"8","author":"Block","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/S1367-5931(99)80068-4_bib75","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0006-8993(97)01499-6","article-title":"Protection against blood brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study","volume":"787","author":"Belayev","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/S1367-5931(99)80068-4_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0091-3057(98)00154-3","article-title":"The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration","volume":"62","author":"Knapp","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/S1367-5931(99)80068-4_bib77","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0091-3057(98)00038-0","article-title":"Rolipram, an antidepressant that increases the availability of cAM P transiently enhances wakefulness in rats","volume":"60","author":"Lelkes","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/S1367-5931(99)80068-4_reference0390","first-page":"47","article-title":"Crohn's disease","author":"Rogers","year":"1998","journal-title":"Clin Persp Gastroenterol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib79","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0006-2952(98)00260-3","article-title":"Reduced DNA synthesis and cell viability in small lung call carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors","volume":"56","author":"Shafer","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib80","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.V92.7.2484","article-title":"Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia","volume":"92","author":"Kil","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S1367-5931(99)80068-4_bib81","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2337\/diabetes.47.4.570","article-title":"The phosphodiesterase inhibitors pentoxifylline, and rolipram prevent diabetes in NOD mice","volume":"47","author":"Liang","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/S1367-5931(99)80068-4_bib82","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0006-2952(97)00211-6","article-title":"Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4","volume":"54","author":"Miyamoto","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1367-5931(99)80068-4_bib83","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0022-5347(01)62833-7","article-title":"The effect of the specific phosphodiesterase IV inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo","volume":"160","author":"Becker","year":"1998","journal-title":"J Urology"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593199800684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593199800684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:14:49Z","timestamp":1761272089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593199800684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["S1367593199800684"],"URL":"https:\/\/doi.org\/10.1016\/s1367-5931(99)80068-4","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[1999,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1367-5931(99)80068-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}